Education
About Us
Working with TipRanks
Follow Us
Inflarx N.V. (IFRX)
NASDAQ:IFRX
IFRX Stock Chart & Stats
$0.93
-$0.16(-6.27%)
At close: 4:00 PM EST
$0.93
-$0.16(-6.27%)
Day’s Range― - ―
52-Week Range$0.71 - $1.94
Previous CloseN/A
Volume66.97K
Average Volume (3M)388.55K
Market Cap
$61.45M
Enterprise Value$48.21M
Total Cash (Recent Filing)$44.65M
Total Debt (Recent Filing)$970.86K
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Mar 19, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding67,133,270
10 Day Avg. Volume171,157
30 Day Avg. Volume388,545
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.29
Price to Sales (P/S)847.69
P/FCF Ratio-2.89
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue767.22
Enterprise Value/Gross Profit-9.33
Enterprise Value/Ebitda-1.22
Forecast
1Y Price Target
$6.00Price Target Upside545.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$73.85K
Bulls Say, Bears Say
Bulls Say
Broad Therapeutic PotentialINF904 produced rapid, meaningful anti-inflammatory effects in chronic spontaneous urticaria and hidradenitis suppurativa, suggesting potential value as a single oral therapy across multiple inflammatory conditions.
Financial Runway And Resource AllocationCost reductions, workforce realignment, and cuts to non-core commercial spending extend the company's cash runway and enable concentrated investment in izicopan's clinical development.
Safety ProfileIzicopan's oral formulation exhibited a clean liver safety profile with minimal inhibition of key liver enzymes, reducing the risk of hepatotoxicity and supporting regulator confidence in its development.
Bears Say
Competitive LandscapeContinued market availability of the competing drug despite regulatory hesitations could limit izicopan's immediate market uptake and reduce near-term commercial opportunity.
Pipeline Concentration RiskSignificant workforce reductions and cuts to vilobelimab commercial activities de-prioritize that program and narrow the company's pipeline, increasing reliance on a smaller set of assets.
Study Design ConcernsKey efficacy data were generated in an open-label study without a placebo control, which weakens confidence in the magnitude of treatment benefit and complicates regulatory assessment.
InflaRx News
IFRX FAQ
What was Inflarx N.V.’s price range in the past 12 months?
Inflarx N.V. lowest stock price was $0.71 and its highest was $1.94 in the past 12 months.
What is Inflarx N.V.’s market cap?
Inflarx N.V.’s market cap is $61.45M.
When is Inflarx N.V.’s upcoming earnings report date?
Inflarx N.V.’s upcoming earnings report date is Mar 19, 2026 which is in 13 days.
How were Inflarx N.V.’s earnings last quarter?
Inflarx N.V. released its earnings results on Oct 30, 2025. The company reported -$0.209 earnings per share for the quarter, missing the consensus estimate of -$0.176 by -$0.034.
Is Inflarx N.V. overvalued?
According to Wall Street analysts Inflarx N.V.’s price is currently Undervalued.
Does Inflarx N.V. pay dividends?
Inflarx N.V. does not currently pay dividends.
What is Inflarx N.V.’s EPS estimate?
Inflarx N.V.’s EPS estimate is -0.17.
How many shares outstanding does Inflarx N.V. have?
Inflarx N.V. has 67,133,270 shares outstanding.
What happened to Inflarx N.V.’s price movement after its last earnings report?
Inflarx N.V. reported an EPS of -$0.209 in its last earnings report, missing expectations of -$0.176. Following the earnings report the stock price went down -4.348%.
Which hedge fund is a major shareholder of Inflarx N.V.?
Currently, no hedge funds are holding shares in IFRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InflaRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (545.16% Upside)
$6.00 (545.16% Upside)
Blogger Sentiment
Bullish
IFRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.92%
Trailing 12-Months
Company Description
Inflarx N.V.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
IFRX Stock 12 Month Forecast
Average Price Target
$6.00
▲(545.16% Upside)
Technical Analysis
Oramed Pharm
―
Atara Biotherapeutics
―
Anixa Biosciences
―
Clene
―
Acumen Pharmaceuticals
―
Ownership Overview
―
Insiders
0.07% Mutual Funds
20.36% Other Institutional Investors
79.57% Public Companies and
Individual Investors